Evaluation of Endoplasmic Reticulum Stress in Patients With Recurrent Pregnancy Loss

NCT04455256 | Completed

• 1 other identifier: tgk-xbp
• Study Type: observational
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate endoplasmic reticulum stress in women with recurrent pregnancy loss and those who had healthy births in the same age group. The level of the unfolded protein X box binding protein 1 (XBP-1) is measured. It is aimed to show the effect of endoplasmic reticulum stress on recurrent pregnancy loss.

Conditions

Recurrent Pregnancy Loss; Endoplasmic Reticulum Stress

Outcome Measures

Primary Outcomes (1)

• Show the effect of endoplasmic reticulum stress on recurrent pregnancy loss

  Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.

  3 months

Study Arms (2)

recurrent pregnancy loss group

Women between the ages of 18 and 45 who had a history of miscarriage under 3 weeks and above 22 weeks were included in this group.

Other: x box binding protein

women who had healthy birth

Women between the ages of 18-45 who have not had a history of pregnancy loss and who have had at least one healthy birth and no known chronic diseases are included in this group.

Other: x box binding protein

Interventions

x box binding protein OTHER

Serum value (pg / mL) of x box binding protein (XBP-1), which is one of the unfolded proteins indicating endoplasmic reticulum stress, is measured.

recurrent pregnancy loss group; women who had healthy birth

Eligibility Criteria

• Age: 18 Years - 45 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Loss of 3 or more pregnancy between the ages of 18 and 45 and women who have given at least 1 healthy birth in the same age group.

You may qualify if:

• with three or more miscarriages before 20 th week of gestation
• had no chronic or acute inflammatory disease
• used no steroids, anti-inflammatory, or antioxidant medications

You may not qualify if:

• had inflammatory diseases
• had systemic disease
• Anatomical abnormalities, infectious, endocrine, or genetic etiologies

Sponsors & Collaborators

• Kanuni Sultan Suleyman Training and Research Hospital: lead

Study Sites (1)

Pinar Yalcin Bahat

Istanbul, İ̇stanbul, 34000, Turkey (Türkiye)

Location

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 28, 2020
• First Posted: July 2, 2020
• Study Start: March 20, 2020
• Primary Completion: July 1, 2020
• Study Completion: July 7, 2020
• Last Updated: July 16, 2020

Record last verified: 2020-07

Data Sharing

• IPD Sharing: Will share

Locations

TU (1)